mrus-10q_20210630.htm
false 2021 Q2 Merus N.V. 0001651311 --12-31 00-0000000 P1Y5M P6Y1M6D 0001651311 2021-01-01 2021-06-30 xbrli:shares 0001651311 2021-07-30 iso4217:USD 0001651311 2021-06-30 0001651311 2020-12-31 iso4217:EUR xbrli:shares 0001651311 mrus:CollaborationRevenueMember 2021-04-01 2021-06-30 0001651311 mrus:CollaborationRevenueMember 2020-04-01 2020-06-30 0001651311 mrus:CollaborationRevenueMember 2021-01-01 2021-06-30 0001651311 mrus:CollaborationRevenueMember 2020-01-01 2020-06-30 0001651311 mrus:CollaborationRevenueRelatedPartyMember 2021-04-01 2021-06-30 0001651311 mrus:CollaborationRevenueRelatedPartyMember 2020-04-01 2020-06-30 0001651311 mrus:CollaborationRevenueRelatedPartyMember 2021-01-01 2021-06-30 0001651311 mrus:CollaborationRevenueRelatedPartyMember 2020-01-01 2020-06-30 0001651311 2021-04-01 2021-06-30 0001651311 2020-04-01 2020-06-30 0001651311 2020-01-01 2020-06-30 iso4217:USD xbrli:shares 0001651311 mrus:LillyCollaborationMember 2021-01-01 2021-06-30 0001651311 mrus:LillyCollaborationMember 2020-01-01 2020-06-30 0001651311 2019-12-31 0001651311 2020-06-30 0001651311 us-gaap:CommonStockMember 2019-12-31 0001651311 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001651311 us-gaap:RetainedEarningsMember 2019-12-31 0001651311 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001651311 us-gaap:CommonStockMember 2020-01-01 2020-03-31 0001651311 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-03-31 0001651311 2020-01-01 2020-03-31 0001651311 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-03-31 0001651311 us-gaap:RetainedEarningsMember 2020-01-01 2020-03-31 0001651311 us-gaap:CommonStockMember 2020-03-31 0001651311 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0001651311 us-gaap:RetainedEarningsMember 2020-03-31 0001651311 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0001651311 2020-03-31 0001651311 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0001651311 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0001651311 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0001651311 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0001651311 us-gaap:CommonStockMember 2020-06-30 0001651311 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0001651311 us-gaap:RetainedEarningsMember 2020-06-30 0001651311 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0001651311 us-gaap:CommonStockMember 2020-12-31 0001651311 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001651311 us-gaap:RetainedEarningsMember 2020-12-31 0001651311 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001651311 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001651311 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001651311 2021-01-01 2021-03-31 0001651311 us-gaap:CommonStockMember mrus:LillyMember 2021-01-01 2021-03-31 0001651311 us-gaap:AdditionalPaidInCapitalMember mrus:LillyMember 2021-01-01 2021-03-31 0001651311 us-gaap:RetainedEarningsMember mrus:LillyMember 2021-01-01 2021-03-31 0001651311 us-gaap:AccumulatedOtherComprehensiveIncomeMember mrus:LillyMember 2021-01-01 2021-03-31 0001651311 mrus:LillyMember 2021-01-01 2021-03-31 0001651311 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001651311 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001651311 us-gaap:CommonStockMember 2021-03-31 0001651311 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001651311 us-gaap:RetainedEarningsMember 2021-03-31 0001651311 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001651311 2021-03-31 0001651311 us-gaap:CommonStockMember 2021-04-01 2021-06-30 0001651311 us-gaap:AdditionalPaidInCapitalMember 2021-04-01 2021-06-30 0001651311 us-gaap:RetainedEarningsMember 2021-04-01 2021-06-30 0001651311 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-04-01 2021-06-30 0001651311 us-gaap:CommonStockMember 2021-06-30 0001651311 us-gaap:AdditionalPaidInCapitalMember 2021-06-30 0001651311 us-gaap:RetainedEarningsMember 2021-06-30 0001651311 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-06-30 0001651311 mrus:UnderwrittenPublicOfferingMember 2021-01-21 2021-01-21 0001651311 mrus:UnderwrittenPublicOfferingMember 2021-01-21 0001651311 us-gaap:MoneyMarketFundsMember 2021-06-30 0001651311 us-gaap:MoneyMarketFundsMember 2020-12-31 0001651311 mrus:CorporatePaperNotesAndBondsMember 2021-06-30 0001651311 mrus:CorporatePaperNotesAndBondsMember 2020-12-31 0001651311 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2021-06-30 0001651311 us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember 2020-12-31 0001651311 us-gaap:USTreasurySecuritiesMember 2021-06-30 0001651311 us-gaap:USTreasurySecuritiesMember 2020-12-31 0001651311 us-gaap:CashEquivalentsMember 2021-06-30 0001651311 us-gaap:CashEquivalentsMember 2020-12-31 0001651311 mrus:MarketableSecuritiesCurrentMember 2021-06-30 0001651311 mrus:MarketableSecuritiesCurrentMember 2020-12-31 0001651311 mrus:LillyCollaborationsAgreementMember 2021-01-18 0001651311 mrus:LillyCollaborationsAgreementMember 2021-01-18 2021-01-18 0001651311 mrus:LillyCollaborationsAgreementMember 2021-02-12 0001651311 mrus:IncyteCollaborationAndLicenseAgreementMember mrus:LicenseAndRelatedActivitiesMember 2017-01-23 2017-01-23 iso4217:EUR 0001651311 mrus:SecondONOResearchAndLicenseAgreementMember 2018-03-14 0001651311 mrus:SecondONOResearchAndLicenseAgreementMember 2018-03-14 2018-03-14 mrus:Antibody 0001651311 mrus:SimcereCollaborationAndLicenseAgreementMember 2018-01-01 2018-01-31 0001651311 mrus:SimcereCollaborationAndLicenseAgreementMember 2018-01-31 mrus:PerformanceObligation 0001651311 mrus:SimcereCollaborationAndLicenseAgreementMember us-gaap:ResearchAndDevelopmentArrangementMember mrus:LicenseAndPerformanceMember 2018-01-01 2018-01-31 0001651311 mrus:SimcereCollaborationAndLicenseAgreementMember 2018-08-31 2018-08-31 mrus:Milestone 0001651311 us-gaap:AccountsReceivableMember mrus:IncyteMember 2020-12-31 0001651311 us-gaap:AccountsReceivableMember mrus:LillyMember 2020-12-31 0001651311 us-gaap:AccountsReceivableMember mrus:OtherMember 2020-12-31 0001651311 us-gaap:AccountsReceivableMember mrus:CollaborationAgreementMember 2020-12-31 0001651311 us-gaap:AccountsReceivableMember mrus:IncyteMember 2021-01-01 2021-06-30 0001651311 us-gaap:AccountsReceivableMember mrus:LillyMember 2021-01-01 2021-06-30 0001651311 us-gaap:AccountsReceivableMember mrus:OtherMember 2021-01-01 2021-06-30 0001651311 us-gaap:AccountsReceivableMember mrus:CollaborationAgreementMember 2021-01-01 2021-06-30 0001651311 us-gaap:AccountsReceivableMember mrus:IncyteMember 2021-06-30 0001651311 us-gaap:AccountsReceivableMember mrus:LillyMember 2021-06-30 0001651311 us-gaap:AccountsReceivableMember mrus:OtherMember 2021-06-30 0001651311 us-gaap:AccountsReceivableMember mrus:CollaborationAgreementMember 2021-06-30 0001651311 mrus:UnbilledReceivablesMember mrus:IncyteMember 2020-12-31 0001651311 mrus:UnbilledReceivablesMember mrus:LillyMember 2020-12-31 0001651311 mrus:UnbilledReceivablesMember mrus:OtherMember 2020-12-31 0001651311 mrus:UnbilledReceivablesMember mrus:CollaborationAgreementMember 2020-12-31 0001651311 mrus:UnbilledReceivablesMember mrus:IncyteMember 2021-01-01 2021-06-30 0001651311 mrus:UnbilledReceivablesMember mrus:LillyMember 2021-01-01 2021-06-30 0001651311 mrus:UnbilledReceivablesMember mrus:OtherMember 2021-01-01 2021-06-30 0001651311 mrus:UnbilledReceivablesMember mrus:CollaborationAgreementMember 2021-01-01 2021-06-30 0001651311 mrus:UnbilledReceivablesMember mrus:IncyteMember 2021-06-30 0001651311 mrus:UnbilledReceivablesMember mrus:LillyMember 2021-06-30 0001651311 mrus:UnbilledReceivablesMember mrus:OtherMember 2021-06-30 0001651311 mrus:UnbilledReceivablesMember mrus:CollaborationAgreementMember 2021-06-30 0001651311 mrus:DeferredRevenueMember mrus:IncyteMember 2020-12-31 0001651311 mrus:DeferredRevenueMember mrus:LillyMember 2020-12-31 0001651311 mrus:DeferredRevenueMember mrus:OtherMember 2020-12-31 0001651311 mrus:DeferredRevenueMember mrus:CollaborationAgreementMember 2020-12-31 0001651311 mrus:DeferredRevenueMember mrus:IncyteMember 2021-01-01 2021-06-30 0001651311 mrus:DeferredRevenueMember mrus:LillyMember 2021-01-01 2021-06-30 0001651311 mrus:DeferredRevenueMember mrus:OtherMember 2021-01-01 2021-06-30 0001651311 mrus:DeferredRevenueMember mrus:CollaborationAgreementMember 2021-01-01 2021-06-30 0001651311 mrus:DeferredRevenueMember mrus:IncyteMember 2021-06-30 0001651311 mrus:DeferredRevenueMember mrus:LillyMember 2021-06-30 0001651311 mrus:DeferredRevenueMember mrus:OtherMember 2021-06-30 0001651311 mrus:DeferredRevenueMember mrus:CollaborationAgreementMember 2021-06-30 0001651311 mrus:IncyteMember 2021-04-01 2021-06-30 0001651311 mrus:LillyMember 2021-04-01 2021-06-30 0001651311 mrus:OtherMember 2021-04-01 2021-06-30 0001651311 mrus:CollaborationAgreementMember 2021-04-01 2021-06-30 0001651311 mrus:IncyteMember 2020-04-01 2020-06-30 0001651311 mrus:LillyMember 2020-04-01 2020-06-30 0001651311 mrus:OtherMember 2020-04-01 2020-06-30 0001651311 mrus:CollaborationAgreementMember 2020-04-01 2020-06-30 0001651311 mrus:IncyteMember 2021-01-01 2021-06-30 0001651311 mrus:LillyMember 2021-01-01 2021-06-30 0001651311 mrus:OtherMember 2021-01-01 2021-06-30 0001651311 mrus:CollaborationAgreementMember 2021-01-01 2021-06-30 0001651311 mrus:IncyteMember 2020-01-01 2020-06-30 0001651311 mrus:LillyMember 2020-01-01 2020-06-30 0001651311 mrus:OtherMember 2020-01-01 2020-06-30 0001651311 mrus:CollaborationAgreementMember 2020-01-01 2020-06-30 0001651311 us-gaap:ResearchAndDevelopmentExpenseMember 2021-04-01 2021-06-30 0001651311 us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0001651311 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-06-30 0001651311 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0001651311 us-gaap:GeneralAndAdministrativeExpenseMember 2021-04-01 2021-06-30 0001651311 us-gaap:GeneralAndAdministrativeExpenseMember 2020-04-01 2020-06-30 0001651311 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-06-30 0001651311 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-06-30 xbrli:pure 0001651311 us-gaap:RestrictedStockUnitsRSUMember 2021-01-01 2021-06-30 0001651311 us-gaap:PostemploymentRetirementBenefitsMember 2020-04-01 2020-04-30 0001651311 2020-01-01 2020-12-31 0001651311 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001651311 us-gaap:OtherIncomeMember 2021-01-01 2021-06-30 0001651311 mrus:IncyteMember mrus:MerusNVMember 2021-06-30 0001651311 mrus:IncyteMember mrus:MerusNVMember 2020-12-31

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2021

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to                     

Commission File Number: 001-37773

 

MERUS N.V.

(Exact name of registrant as specified in its charter)

 

 

The Netherlands

Not Applicable

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

 

Yalelaan 62

3584 CM Utrecht

The Netherlands

Not Applicable

(Address of principal executive offices)

(Zip code)

 

+31 85 016 2500

(Registrant’s telephone number, including area code)

 

 

N/A

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

Trading symbol(s)

Name of each exchange on which registered

Common shares, nominal value €0.09 per share

MRUS

The Nasdaq Stock Market LLC

(Nasdaq Global Market)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

 

Accelerated filer

Non-accelerated filer

 

 

Smaller reporting company

 

 

 

 

Emerging growth company

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act). 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

As of July 30, 2021, the registrant had 38,477,796 common shares, nominal value €0.09 per share, outstanding.

 

 

 

 


 

 

 

PART I — FINANCIAL INFORMATION

 

 

 

Item 1. Financial Statements

2

 

 

Condensed Consolidated Balance Sheets
as of June 30, 2021 and December 31, 2020

2

 

 

Condensed Consolidated Statements of Operations and Comprehensive Loss
for the three and six months ended June 30, 2021 and 2020

3

 

 

Condensed Consolidated Statements of Cash Flows
for the six months ended June 30, 2021 and 2020

4

 

 

Condensed Consolidated Statements of Changes in Stockholders’ Equity
for three and six months ended June 30, 2021 and 2020  

5

 

 

Notes to Condensed Consolidated Financial Statements

6

 

 

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

15

 

 

Item 3. Quantitative and Qualitative Disclosures About Market Risk

21

 

 

Item 4. Controls and Procedures

21

 

 

PART II — OTHER INFORMATION

 

 

 

Item 1. Legal Proceedings

23

 

 

Item 1A. Risk Factors

23

 

 

Item 5. Other Information

65

 

 

Item 6. Exhibits

65

 

 

Signatures

66

 

 


 

 

Cautionary Note Regarding Forward-looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements within the meaning of the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. All statements other than statements of historical fact contained in this Quarterly Report on Form 10-Q, including without limitation statements regarding our plans to develop and commercialize our product candidates, the timing of our ongoing or planned clinical trials, the timing of and our ability to obtain and maintain regulatory approvals, the anticipated impact of the COVID-19 pandemic on our business and operations, the clinical utility of our product candidates, our commercialization, marketing and manufacturing capabilities and strategy, our expectations surrounding our collaborations, our expectations about the willingness of healthcare professionals to use our product candidates, the sufficiency of our cash, cash equivalents and investments, and the plans and objectives of management for future operations and capital expenditures are forward-looking statements.

The forward-looking statements in this Quarterly Report on Form 10-Q are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q and are subject to a number of known and unknown risks, uncertainties, assumptions and other important factors, including those described under the sections in this Quarterly Report on Form 10-Q entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in this Quarterly Report on Form 10-Q.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond our control, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

 

SUMMARY RISK FACTORS

Our business is subject to numerous risks and uncertainties, including those described in Part II, Item 1A. “Risk Factors” in this Quarterly Report on Form 10-Q. You should carefully consider these risks and uncertainties when investing in our common shares. The principal risks and uncertainties affecting our business include the following:

 

 

We have incurred significant net losses since inception and we expect to continue to incur significant net losses for the foreseeable future.

 

 

We have a limited operating history, have not successfully completed any clinical trials, and have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and predict our future success and viability.

 

 

We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce or eliminate one or more of our research and drug development programs or future commercialization efforts.

 

 

The outcome of preclinical testing and early phases of clinical trials may not be predictive of the success of later phases of clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities.

 

 

The clinical trial and regulatory approval processes are lengthy, time consuming and inherently unpredictable, and we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.

 

 

Our antibody candidates may have serious adverse, undesirable or unacceptable side effects which may delay or prevent marketing approval. If such side effects are identified during the development of our antibody candidates or following approval, if any, we may need to abandon our development of such antibody candidates, the commercial profile of any approved label may be limited, or we may be subject to other significant negative consequences following marketing approval, if any.

 

 


 

 

We depend on enrollment of patients in our clinical trials for our antibody candidates, including patients having NRG1 fusion tumors, which are rare, tumorigenic genomic events. If we are unable to enroll patients in our clinical trials, including those having these rare tumorigenic events, our research and development efforts and business, financial condition and results of operations could be materially adversely affected.

 

 

We rely, and expect to continue to rely, on third parties, including independent clinical investigators and contract research organizations or CROs, to conduct our pre-clinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our antibody candidates and our business could be substantially harmed.

 

 

 

Due to our limited resources and access to capital, we must, and have in the past decided to prioritize development of certain antibody candidates over other potential candidates. These decisions may prove to have been wrong and may adversely affect our revenues.

 

 

The competition for qualified personnel is particularly intense in our industry. If we are unable to retain or hire key personnel, we may not be able to sustain or grow our business.

 

 

 

We operate in highly competitive and rapidly changing industries, and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the product candidates we develop, our commercial opportunities will be negatively impacted.

 

 

Our success depends on our ability to protect our intellectual property and our proprietary technologies. If we are unable to adequately protect our intellectual property and our proprietary technologies, or obtain and maintain issued patents which are sufficient to protect our product candidates, others could compete against us more directly, which would negatively impact our business.

 

 

 

Our existing collaborations are important to our business and future licenses may also be important to us, and if we are unable to maintain any of these collaborations, or if these arrangements are not successful, our business could be adversely affected.

 

 

The COVID-19 pandemic caused by the novel coronavirus has and may continue to adversely impact our business, including our pre-clinical studies and clinical trials, financial condition and results of operations.

 

 

 

 

 

 


 

 

PART I – FINANCIAL INFORMATION

Item 1.Financial Statements

MERUS N.V.

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

(Amounts in thousands, except per share data)

 

 

 

June 30,

2021

 

 

December 31,

2020

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

311,472

 

 

$

163,082

 

Marketable securities

 

 

41,280

 

 

 

44,673

 

Accounts receivable

 

 

1,471

 

 

 

46

 

Accounts receivable (related party)

 

 

2,212

 

 

 

1,623

 

Prepaid expenses and other current assets

 

 

10,559

 

 

 

8,569

 

Total current assets

 

 

366,994

 

 

 

217,993

 

Property and equipment, net

 

 

3,596

 

 

 

4,115

 

Operating lease right-of-use assets

 

 

4,762

 

 

 

3,907

 

Intangible assets, net

 

 

2,608

 

 

 

2,843

 

Deferred tax assets

 

 

140

 

 

 

410

 

Other assets

 

 

1,483

 

 

 

1,949

 

Total assets

 

$

379,583

 

 

$

231,217

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

6,160

 

 

$

3,126

 

Accrued expenses and other liabilities

 

 

24,529

 

 

 

21,803

 

Income taxes payable

 

 

 

 

 

206

 

Current portion of lease obligation

 

 

1,597

 

 

 

1,432

 

Current portion of deferred revenue

 

 

13,184

 

 

 

625

 

Current portion of deferred revenue (related party)

 

 

18,937

 

 

 

19,554

 

Total current liabilities

 

 

64,407

 

 

 

46,746

 

Lease obligation

 

 

3,198

 

 

 

2,521

 

Deferred revenue, net of current portion

 

 

25,338

 

 

 

237

 

Deferred revenue, net of current portion (related party)

 

 

67,553

 

 

 

79,450

 

Total liabilities

 

 

160,496

 

 

 

128,954

 

Commitments and contingencies - Note 6

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

 

 

Common shares, €0.09 par value; 45,000,000 shares authorized;

38,444,580 and 31,602,953 shares issued and outstanding as at

June 30, 2021 and December 31, 2020, respectively

 

$

3,959

 

 

$

3,211

 

Additional paid-in capital

 

 

649,627

 

 

 

490,093

 

Accumulated other comprehensive income

 

 

3,155

 

 

 

9,071

 

Accumulated deficit

 

 

(437,654

)

 

 

(400,112

)

Total stockholders’ equity

 

 

219,087

 

 

 

102,263

 

Total liabilities and stockholders’ equity

 

$

379,583

 

 

$

231,217

 

 

See accompanying notes to the Unaudited Condensed Consolidated Financial Statements.

2


 

MERUS N.V.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(UNAUDITED)

(Amounts in thousands, except per share data)

 

 

 

Three Months Ended

June 30,

 

 

Six Months Ended

June 30,

 

 

 

2021

 

 

2020

 

 

2021

 

 

2020

 

Collaboration revenue

 

$

5,118

 

 

$

184

 

 

$

6,717

 

 

$

512

 

Collaboration revenue (related party)

 

 

7,261

 

 

 

5,872

 

 

 

14,012

 

 

 

11,845

 

Total revenue

 

 

12,379

 

 

 

6,056

 

 

 

20,729

 

 

 

12,357

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

 

24,612

 

 

 

13,709

 

 

 

45,418

 

 

 

30,696

 

General and administrative

 

 

10,569

 

 

 

8,043

 

 

 

19,902

 

 

 

16,925

 

Total operating expenses

 

 

35,181

 

 

 

21,752

 

 

 

65,320

 

 

 

47,621

 

Operating loss

 

 

(22,802

)

 

 

(15,696

)

 

 

(44,591

)

 

 

(35,264

)

Other (loss) income, net:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Interest (expense) income, net

 

 

(51

)

 

 

99

 

 

 

(133

)

 

 

379

 

Foreign exchange (losses) gains, net

 

 

(4,525

)

 

 

(2,346

)

 

 

7,678

 

 

 

539

 

Other (losses) gains, net

 

 

52

 

 

 

 

 

 

(385

)

 

 

 

Total other (loss) income, net

 

 

(4,524

)

 

 

(2,247

)

 

 

7,160

 

 

 

918

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss before income taxes

 

 

(27,326

)

 

 

(17,943

)

 

 

(37,431

)

 

 

(34,346

)

Income tax expense

 

 

62

 

 

 

31

 

 

 

111

 

 

 

128

 

Net loss

 

$

(27,388

)

 

$

(17,974

)

 

$

(37,542

)

 

$

(34,474

)

Other comprehensive income (loss):

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Currency translation adjustment

 

 

3,475

 

 

 

2,201

 

 

 

(5,916

)

 

 

(906

)

Comprehensive loss

 

$

(23,913

)

 

$

(15,773

)

 

$

(43,458

)

 

$

(35,380

)

Net loss per share attributable to common stockholders:

      Basic and diluted

 

$

(0.71

)

 

$

(0.54

)

 

$

(1.01

)

 

$

(1.22

)

Weighted-average common shares outstanding:

      Basic and diluted

 

 

38,376

 

 

 

29,034

 

 

 

37,299

 

 

 

28,990

 

 

See accompanying notes to the Unaudited Condensed Consolidated Financial Statements.

3


 

MERUS N.V.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(UNAUDITED)

(Amounts in thousands)

 

 

 

Six Months Ended

June 30,

 

 

 

2021

 

 

2020

 

CASH FLOWS FROM OPERATING ACTIVITIES:

 

 

 

 

 

 

 

 

Net loss

 

$

(37,542

)

 

$

(34,474

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

 

Depreciation and amortization of property and equipment

 

 

634

 

 

 

532

 

Amortization of intangible assets

 

 

147

 

 

 

134

 

Foreign exchange gain

 

 

(7,611

)

 

 

(503

)

Loss on disposal of property and equipment

 

 

 

 

 

16

 

Stock-based compensation expense

 

 

7,959

 

 

 

3,483

 

Amortization of premium (discount) on investments

 

 

48

 

 

 

(79

)

Deferred tax expense

 

 

270

 

 

 

78

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

 

Accounts receivable

 

 

(2,097

)

 

 

681

 

Operating lease right-of-use assets and lease obligations

 

 

(11

)

 

 

3

 

Prepaid expenses and other current assets

 

 

(1,852

)

 

 

(6,441

)

Accounts payable

 

 

3,190

 

 

 

(599

)

Accrued expenses and other liabilities

 

 

3,207

 

 

 

2,556

 

Deferred revenue

 

 

28,704

 

 

 

(9,255

)

Net cash used in operating activities

 

$

(4,954

)

 

$

(43,868

)

CASH FLOWS FROM INVESTING ACTIVITIES:

 

 

 

 

 

 

 

 

Purchases of marketable securities

 

$

(24,850

)

 

$

(28,947

)

Proceeds from maturities of marketable securities

 

 

28,163

 

 

 

28,181

 

Purchases of property and equipment

 

 

(260

)

 

 

(512

)

Net cash provided by (used in) investing activities

 

$

3,053

 

 

$

(1,278

)

CASH FLOWS FROM FINANCING ACTIVITIES:

 

 

 

 

 

 

 

 

Payment of offering costs

 

$

 

 

$

(164

)

Proceeds from issuance of common stock, net

 

 

129,398

 

 

 

 

Proceeds from issuance of common stock - Lilly

 

 

16,477

 

 

 

 

Proceeds from stock options exercised

 

 

6,728

 

 

 

893

 

Repurchase of restricted stock units

 

 

(285

)

 

 

 

Net cash provided by financing activities

 

$

152,318

 

 

$

729

 

Foreign exchange impact on cash, cash equivalents and restricted cash

 

 

(2,027

)

 

 

(1,107

)

Net increase (decrease) in cash, cash equivalents and restricted cash

 

 

148,390

 

 

 

(45,524

)

Cash, cash equivalents, and restricted cash, beginning of period

 

 

163,283

 

 

 

197,813

 

Cash, cash equivalents, and restricted cash, end of period

 

$

311,673

 

 

$

152,289

 

SUPPLEMENTAL DISCLOSURES:

 

 

 

 

 

 

 

 

Non-cash right-of-use assets acquired from operating lease obligations

 

$

1,662

 

 

$

 

Income taxes paid

 

$

491

 

 

$

25

 

Non-cash purchases of property, equipment and intangibles

 

$

22

 

 

$

35

 

Non-cash issuance of stock options

 

$

573

 

 

$

 

CASH, CASH EQUIVALENTS AND RESTRICTED CASH

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

311,472

 

 

$

152,088

 

Restricted cash included in non-current other assets

 

 

201

 

 

 

201

 

 

 

$

311,673

 

 

$

152,289

 

 

See accompanying notes to the Condensed Consolidated Financial Statements.

4


 

MERUS N.V.

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY

(UNAUDITED)

(Amounts in thousands, except share amounts)

 

 

 

Common Stock

 

 

Additional

Paid-In

 

 

Accumulated

 

 

Accumulated

Other

Comprehensive

 

 

Total

Stockholders’

 

 

 

Shares

 

 

Amount

 

 

Capital

 

 

Deficit

 

 

Income (Loss)

 

 

Equity

 

Balance at January 1, 2020

 

 

28,882,217

 

 

$

2,918

 

 

$

441,395

 

 

$

(314,599

)

 

$

1,586

 

 

$

131,300

 

Exercise of stock options and vesting of restricted stock units

 

 

127,205

 

 

 

13

 

 

 

589

 

 

 

 

 

 

 

 

 

602

 

Stock-based compensation

 

 

 

 

 

 

 

 

2,291

 

 

 

 

 

 

 

 

 

2,291

 

Currency translation adjustment

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(3,107

)

 

 

(3,107

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

(16,500

)

 

 

 

 

 

(16,500

)

Balance at March 31, 2020

 

 

29,009,422

 

 

 

2,931

 

 

 

444,275

 

 

 

(331,099

)

 

 

(1,521

)

 

 

114,586

 

Exercise of stock options and vesting of restricted stock units

 

 

37,922

 

 

 

4

 

 

 

287

 

 

 

 

 

 

 

 

 

291

 

Stock-based compensation

 

 

 

 

 

 

 

 

1,192

 

 

 

 

 

 

 

 

 

1,192

 

Currency translation adjustment

 

 

 

 

 

 

 

 

 

 

 

 

 

 

2,201

 

 

 

2,201

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(17,974

)

 

 

 

 

 

(17,974

)

Balance at June 30, 2020

 

 

29,047,344

 

 

$

2,935

 

 

$

445,754

 

 

$

(349,073

)

 

$

680

 

 

$

100,296

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Balance at January 1, 2021

 

 

31,602,953

 

 

$

3,211

 

 

$

490,093

 

 

$

(400,112

)

 

$

9,071

 

 

$

102,263

 

Issuance of common stock, net

 

 

5,575,757

 

 

 

610

 

 

 

128,793

 

 

 

 

 

 

 

 

 

129,403

 

Issuance of common stock - Lilly

 

 

706,834

 

 

 

77

 

 

 

16,400

 

 

 

 

 

 

 

 

 

16,477

 

Exercise of stock options and vesting of restricted stock units

 

 

386,097

 

 

 

42

 

 

 

4,782

 

 

 

 

 

 

 

 

 

4,824

 

Repurchase of restricted stock units

 

 

 

 

 

 

 

 

(285

)

 

 

 

 

 

 

 

 

(285

)

Stock-based compensation

 

 

 

 

 

 

 

 

3,400

 

 

 

 

 

 

 

 

 

3,400

 

Currency translation adjustment

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(9,391

)

 

 

(9,391

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

(10,154

)

 

 

 

 

 

(10,154

)

Balance at March 31, 2021

 

 

38,271,641

 

 

 

3,940

 

 

 

643,183

 

 

 

(410,266

)

 

 

(320

)

 

 

236,537

 

Exercise of stock options and vesting of restricted stock units

 

 

172,939

 

 

 

19

 

 

 

1,885

 

 

 

 

 

 

 

 

 

1,904

 

Stock-based compensation

 

 

 

 

 

 

 

 

4,559

 

 

 

 

 

 

 

 

 

4,559

 

Currency translation adjustment

 

 

 

 

 

 

 

 

 

 

 

 

 

 

3,475

 

 

 

3,475

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

(27,388

)

 

 

 

 

 

(27,388

)

Balance at June 30, 2021

 

 

38,444,580

 

 

$

3,959

 

 

$

649,627

 

 

$

(437,654

)

 

$

3,155

 

 

$

219,087

 

 

See accompanying notes to the Unaudited Condensed Consolidated Financial Statements.

5


 

MERUS N.V.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(UNAUDITED)

1. Overview

Merus N.V. is a clinical-stage oncology company developing innovative antibody therapeutics, headquartered in Utrecht, the Netherlands. Merus US, Inc. is a wholly-owned subsidiary of Merus N.V. located at 139 Main Street, Cambridge, Massachusetts, United States (collectively, the “Company”).

Since inception, the Company has generated an accumulated deficit of $437.7 million as of June 30, 2021. The Company expects to continue to incur significant expenses and operating losses for the foreseeable future as its antibody candidates advance through discovery, pre-clinical development and clinical trials and as it seeks regulatory approval and pursues commercialization of any approved antibody candidate.

As a result, the Company may need additional financing to support its continuing operations. Until the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operations through public equity offerings, debt financings, or other sources, which may include collaborations, business development and licensing opportunities with third parties. Adequate additional financing may not be available to the Company on acceptable terms, or at all. The Company’s inability to raise capital as and when needed would have a negative impact on its financial condition and ability to pursue its business strategy. The Company will need to generate significant revenues to achieve profitability and may never do so.

On January 21, 2021, the Company completed an offering of common shares in which the Company sold 5,575,757 common shares, including 727,272 common shares pursuant to the underwriters’ option to purchase additional shares, at a price to the public of $24.75 for aggregate net proceeds of $129.4 million.

Based on the Company’s current operating plan, the Company expects that its existing cash and cash equivalents and marketable securities of $352.8 million as of June 30, 2021, will fund the Company’s operations into the second half of 2024.

2. Summary of Significant Accounting Policies

The principal accounting policies applied in the preparation of these unaudited condensed consolidated financial statements are described in the Company’s audited financial statements as of and for the year ended December 31, 2020, and the notes thereto, which are included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 16, 2021 (the “Annual Report on Form 10-K”). There have been no material changes in the Company’s significant accounting policies during the six months ended June 30, 2021.

Basis of Presentation

The Company prepared its unaudited consolidated condensed financial statements in compliance with generally accepted accounting principles in the U.S. ("U.S. GAAP"). Any reference in these notes to applicable guidance is meant to refer to authoritative U.S. GAAP as found in the Accounting Standards Codification ("ASC") and Accounting Standards Update ("ASU") of the Financial Accounting Standards Board ("FASB").

The unaudited condensed consolidated financial statements include the accounts of Merus N.V. and its wholly owned, controlled subsidiary, Merus US, Inc. All intercompany transactions and balances of subsidiaries have been eliminated in consolidation. In the opinion of management, these financial statements reflect all adjustments, all of which are of a normal and recurring nature, necessary for a fair presentation of the results for the reported interim periods. The Company considers events or transactions that occur after the balance sheet date but before the unaudited condensed consolidated financial statements are issued to provide additional evidence relative to certain estimates or to identify matters that require additional disclosure. The three months ended June 30, 2021 and 2020 are referred to as the second quarter of 2021 and 2020, respectively. The results of operations for interim periods are not necessarily indicative of results to be expected for the full year or any other interim period.

The unaudited condensed consolidated financial statements presented herein do not contain the required disclosures under U.S. GAAP for annual financial statements. Therefore, these unaudited condensed consolidated financial statements should be read in conjunction with the annual audited consolidated financial statements and related notes as of and for the year ended December 31, 2020, included in the Annual Report on Form 10-K.

Going Concern

At each reporting period, the Company evaluates whether there are conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company

6


 

is required to make certain additional disclosures if it concludes substantial doubt exists and it is not alleviated by the Company’s plans or when its plans alleviate substantial doubt about the Company’s ability to continue as a going concern.

The Company’s evaluation entails analyzing prospective operating budgets and forecasts for expectations of the Company’s cash needs, and comparing those needs to the current cash, cash equivalent and marketable securities balances. After considering the Company’s current research and development plans, the timing expectations related to the progress of its clinical-stage programs and its plans to pursue commercialization of any antibody candidate, if approved, and after considering its existing cash, cash equivalents and marketable securities as of June 30, 2021, the Company did not identify conditions or events that raise substantial doubt about the Company’s ability to continue as a going concern within one year from the date these financial statements were issued.

Recently Adopted Accounting Pronouncements

In August 2018, the FASB issued ASU 2018-15, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Customer's Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract. The new guidance aligns the requirements for capitalizing implementation costs incurred in a cloud-based hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). This ASU became effective for the Company at the beginning of 2021, but had no impact on amounts or disclosures previously reported or during the period.

In November 2018, the FASB issued ASU 2018-18, Collaborative Arrangements (Topic 808), which clarifies that certain transactions between collaborative arrangement participants should be accounted for as revenue when the collaborative arrangement participant is a customer in the context of a unit of account and precludes recognizing as revenue consideration received from a collaborative arrangement participant if the participant is not a customer. The ASU became effective for the Company at the beginning of 2021. None of the Company’s arrangements fall within the scope of ASC 808, the adoption of this standard had no impact on amounts or disclosures previously reported or during the period.

3. Investments in Debt Securities

The following tables summarize the Company’s investments in debt securities and their presentation in the condensed consolidated balance sheet:

 

 

June 30,

2021

 

 

December 31,

2020

 

 

 

(in thousands)

 

Money market funds

 

$

14,106

 

 

$

10,156

 

Corporate paper and notes

 

 

43,746

 

 

 

27,978

 

U.S. government agency securities

 

 

 

 

 

9,150

 

U.S. treasuries

 

 

2,534

 

 

 

15,043

 

Total

 

$

60,386

 

 

$

62,327